Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS

SIMPLE SUMMARY: Treatment results of acute myeloid leukemia (AML) in elderly patients are unsatisfactory. We investigated in an open label randomized phase II study whether addition of tosedostat, an aminopeptidase inhibitor, to intensive chemotherapy would improve outcome in this population. 231 AM...

Descripción completa

Detalles Bibliográficos
Autores principales: Janssen, Jeroen, Löwenberg, Bob, Manz, Markus, Bargetzi, Mario, Biemond, Bart, Borne, Peter von dem, Breems, Dimitri, Brouwer, Rolf, Chalandon, Yves, Deeren, Dries, Efthymiou, Anna, Gjertsen, Bjørn-Tore, Graux, Carlos, Gregor, Michael, Heim, Dominik, Hess, Urs, Hoogendoorn, Mels, Jaspers, Aurelie, Jie, Asiong, Jongen-Lavrencic, Mojca, Klein, Saskia, van der Klift, Marjolein, Kuball, Jürgen, van Lammeren-Venema, Danielle, Legdeur, Marie-Cecile, van de Loosdrecht, Arjan, Maertens, Johan, Kooy, Marinus van Marwijk, Moors, Ine, Nijziel, Marten, van Obbergh, Florence, Oosterveld, Margriet, Pabst, Thomas, van der Poel, Marjolein, Sinnige, Harm, Spertini, Olivier, Terpstra, Wim, Tick, Lidwine, van der Velden, Walter, Vekemans, Marie-Christiane, Vellenga, Edo, de Weerdt, Okke, Westerweel, Peter, Stüssi, Georg, van Norden, Yvette, Ossenkoppele, Gert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914531/
https://www.ncbi.nlm.nih.gov/pubmed/33562393
http://dx.doi.org/10.3390/cancers13040672

Ejemplares similares

Ejemplares similares